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A 15-month-old girl, born to the consanguineous parents, was referred with the sign of massive splenomegaly associated with
thrombocytopenia and anemia. Plasma Chitotriosidase estimation was carried out as a screening test and was found to be normal
with reduced activity of β-glucosidase in leucocytes suggestive of Gaucher disease. At the age of 4 years, severe osteoporosis and
cardiomegaly with pulmonary congestion were observed in the child. Molecular analysis for GBA gene has revealed homozygous
status for L444P (c.1448C) in the proband, whereas parents and two elder sisters were found to be heterozygote. Prenatal study
duringthefourthpregnancywascarriedoutfromculturedchorionicvilliforβ-glucosidase,whichwasinthecarrierrange.Further
conﬁrmationof thecarrier statuswas carried out fromamnioticﬂuid DNAand was foundto beheterozygous forL444P (c.1448C)
in the GBA gene. This case demonstrates that children with the sign of splenomegaly with anemia and thrombocytopenia need to
be screened for Gaucher disease, and molecular study can further help to conﬁrm the heterozygous status, where prenatal study
by enzyme investigation demonstrate heterozygous condition.
1.Introduction
Gaucher disease (GD) is an autosomal recessive sphingolipid
disorder resulting from the accumulation of glucocerebro-
side in the cells of macrophage-monocyte system as a
result of a deﬁciency in lysosomal enzyme β-glucosidase
[glucocerebrosidase, E.C. 3.2.1.45], which is encoded by the
GBA gene on chromosome-1 [1]. The three main clinical
types have been delineated according to the absence (type 1,
nonneuronopathic) or the presence (type 2, acute neurono-
pathic, and type 3, sub acute neuronopathic) of neurological
involvement [2]. Glucosylceramide, the accumulated glycol-
ipid, is primarily derived from the phagocytosis and degra-
dation of senescent leukocytes and, to a lesser extent, from
erythrocyte membranes. The glycolipid storage gives rise to
thecharacteristicGauchercells,whicharetypicallypresentin
the bone marrow, liver, spleen, lungs, and other organs. This
contributes to pancytopenia, massive hepatosplenomegaly,
and at times diﬀuse inﬁltrative pulmonary disease. However,
signs like anemia, severe splenomegaly, and hepatomegaly
were observed more frequently in younger patients [3].
2.CaseReport
A 15-month-old female child was referred to our centre with
the clinical sign of massive splenomegaly associated with
thrombocytopenia and anemia. She was delivered after full-
term normal pregnancy. She had seizure immediately after
2 hours of birth and was kept under observation for a day.
Development of the child was normal till 1 year of age. Later
on, her parents noticed sporadic crying and regression of
milestones especially when she stopped walking. Her two
elder sisters were healthy, and there was no family history of
blood transfusion, splenectomy, and recurrent jaundice. She
was referred for plasma chitotriosidase estimation at the age
of 15 months, which was 64.12nmol/hr/mL plasma (normal
range: 28.66–62.94nmol/hr/mL plasma). Ultrasound scan-
ning at 15 months showed the spleen of about 11-12cm.
No active bleeding, hepatomegaly, or lymphadenopathy was
observed. X-ray of the pelvis with lower limbs was found to
be normal. Subsequently, colour Doppler was carried out,
which had shown huge splenomegaly with normal splenic
echotexture and splenic vein measuring 4mm at splenic2 Case Reports in Pediatrics
Figure 1: Proband with hepatomegaly at 4 years of age.
hilum. There was no evidence of periportal varices observed,
and fundoscopy examination was found normal. On sys-
temic examination, central nervous system (CNS) report
showed consciousness with normal eye movements. She had
no focal deﬁcit, power was normal, mild hypotonia with
deep tendon reﬂex (DTR)-brisk was noted. Proband was
referred once again at the age of 2.5 years due to diﬃculty
in walking with persistence of a large abdomen and her
histopathology examination from liver biopsy also showed
characteristic Gaucher cells occupying the sinusoids, and
the spleen biopsy section revealed large cells with ﬁbrillary
cytoplasm and small eccentric nuclei populating red pulp.
Plasma chitotriosidase study was reconﬁrmed and was
found normal 32.00nmol/hr/mL plasma, and β-glucosidase
activity from leucocytes was low 3.8nmol/hr/mg protein
(normalrange:8.0–32.0nmol/hr/mgprotein)suggestingGD
in the proband. At the age of 4 years, due to septicemia
and bleeding from the mouth, proband was operated for
splenectomy. At this time, X-ray of the chest posterior-
anterior view showed cardiomegaly with pulmonary con-
gestion and electrocardiogram (ECG) report revealed mild
left ventricular systolic dysfunction with 40–50% of left
ventricular ejaculation function. Ultrasound scanning at this
time showed an enlarged liver measuring 15.5cm in size
(Figure 1). X-ray of the right tibia/ﬁbula anteroposterior and
lateral view revealed osteoporosis and fracture (Figure 2(a))
and X-ray of the right humerus revealed severe osteoporosis
with cortical irregularity and fracture seen along midshaft
of the humerus (Figure 2(b)). Hematogram investigation at
this time showed Hb-6.7 (N.R.: 13.5–18.0g/dL), total WBC
count-29484 (N.R.: 4,000–11,000/cmm), and platelet count-
45,000 (N.R.: 1, 50,000–4, 50,000/cmm).
Further conﬁrmation of the disease was carried out by
molecularanalysisofGBAgene.Thishasshownhomozygous
status for L444P (c.1448C), conﬁrming GD. Two unaﬀect-
ed elder sisters and parents revealed heterozygous status for
L444P (c.1448C) mutation. During the fourth pregnancy
cultured chorionic villus study was carried out for β-glu-
cosidase, which was in the carrier range 139.58nmol/hr/
mg protein with control value of 328.3nmol/hr/mg protein.
Further conﬁrmation was carried out from amniotic ﬂuid
DNA, which has conﬁrmed heterozygous status of the fetus
for the said mutation.
3. Discussion
The most common signs and symptoms noted in GD
are splenomegaly (95%), hepatomegaly (87%), radiologi-
cal bone disease (81%), thrombocytopenia (50%), anemia
(40%), growth retardation (34%), bone pain (27%), and
bone crisis (9%). A skeletal manifestation is found more
ofteninolderchildren[3].Thefemoralheadandthefemoral
shaft are by far the most frequently involved sites in bone
crisis. However, these episodes occur with some frequency in
humeral heads, vertebral bodies, and ischium of pelvis [4].
In the present case, all these symptoms were observed and in
addition osteoporosis and fracture in lower shaft tibia/ﬁbula,
severe osteoporosis with cortical irregularity and fracture
were seen along the midshaft of the humerus. Cardiomegaly
with pulmonary congestion was also observed at this time,
and it is likely to occur due to frank inﬁltration of lungs by
Gaucher cells [4].
Plasma chitotriosidase, which acts as a screening marker
and shows marked elevated level in Gaucher disease, was
foundto be normal in present case [5].This canbe explained
by the fact that 5-6% of the population who lack this enzyme
as a result of genetic deﬁciency due to an expressional mu-
tation in the human chitotriosidase gene that occurs with
high polymorphic frequency and approximately one-third of
patients with GD are heterozygous for this null allele, and
thus the extent to which GD may increase the activity of
chitotriosidase in the plasma is reduced in these individuals
[6, 7]. Although β-Glucosidase activity in leucocytes or
ﬁbroblasts is the conﬁrmative test for GD followed by
mutation identiﬁcation in GBA gene [8]. Our study is in
accordancewiththisobservationwithsigniﬁcantlylowactiv-
ity of the enzyme in leucocytes followed by identiﬁcation
of L444P mutation in the proband. Identiﬁcation of the
genotype may help in predicting phenotypic expression,
therapeutic response, and carrier screening for genetic
counseling. Presence of L444P (c.1448C) homozygous status
in the proband was useful in detecting carrier status in
both parents, two unaﬀected sisters, and during prenatal
diagnosis. This is one of the most common mutation
observed in non-Jewish populations with a frequency of
31.43% and resulted in substitution of proline for leucine at
position 444(L444P) [9]. This mutation was ﬁrst found in
neuronopathic form (Type II and type III) but later on it was
also found to be associated with the nonneuronopathic form
(Type I) [10].
It has been reported that nonneuronopathic GD is the
most prevalent form (94%) and is diﬀerentiated from the
acute neuronopathic (1%) and chronic neuronopathic (5%)
forms by the absence of central nervous system involvement
[3]. In the present report, hepatosplenomegaly, anemia,
thrombocytopenia, osteoporosis, cardiomegaly, mild hypo-
tonia, and homozygous for L444P (c.1448C) mutation andCase Reports in Pediatrics 3
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Figure 2: (a) X-ray of RT T/F AP/LAT shows osteoporosis and fractures. (b) X-ray of RT humerus shows severe osteoporosis.
normal central nervous system examination suggest Type-I
Gaucher disease.
In such cases the long-term clinical picture is critical
in light of data demonstrating that the eﬃcacy of enzyme
replacement therapy (ERT) with placental-derived prepa-
ration, alglucerase or the recombinant form, imiglucerase
and substrate reduction therapy (e.g., miglustat) can prevent
progressive manifestations of GD and completely or partly
ameliorates disease-associated anemia, thrombocytopenia,
organomegaly, bone pain, and bone crises [11].
As per our knowledge, this is the only case study from
India where screening to conﬁrmative molecular analysis
has been carried out in the family. It clearly demonstrates
that primary screening by plasma chitotriosidase followed by
conﬁrmative enzyme study of β-Glucosidase together with
mutation identiﬁcation can help the family to corroborate
the prenatal and postnatal diagnosis for an early therapeutic
approach, before irreversible clinical manifestation occurs.
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